Cover Image
Market Research Report
Product code 
1084196

Oral Biologics Market, By Drug Class, By Disease Indication, By Distribution channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published: | Coherent Market Insights | 197 Pages | Delivery time: 2-3 business days

Price

Back to Top
Oral Biologics Market, By Drug Class, By Disease Indication, By Distribution channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Published: May 26, 2022
Coherent Market Insights
Content info: 197 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

Biological drugs refer to therapeutic products derived from living organisms or contain components of living organisms. Biological drugs are widely used in the treatment of number of diseases including diabetes, plaque psoriasis, arthritis, Crohn's disease, and ulcerative colitis.

Oral biologics products refer to the biological drugs taken from oral disease indication. Currently, majority of biological drugs are administrated by parenteral route and only guanylate cyclase-c agonist class of drug is approved oral biologics in market.

However, key players in the market are involved in development of orally administered glucagon-like peptide 1 (GLP-1) receptor agonist, recombinant enzyme, somatostatin analogue, and various hormone for different indications.

Market Dynamics

Increasing number of inorganic strategies such as collaborations, partnerships, mergers, and acquisition by key players is a major factor driving growth of the market. For instance, in February 2021, Biocon Limited announced merger with International Diabetes Federation (IDF), an insulin biosimilar company, and the merger focuses on the research and development of Biocon's biologics segment and promote the affordable access of insulin products manufactured by Biocon to the diabetes patients globally.

Key features of the study:

  • This report provides in-depth analysis of the global oral biologics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global oral biologics market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., AbbVie Inc., Enteris BioPharma, Inc., Chiasma, Inc. and Allena Pharmaceuticals, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global oral biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oral biologics market

Detailed Segmentation:

  • Global Oral Biologics Market, By Drug Class:
  • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
  • Hormone
  • Recombinant Enzyme
  • Guanylate Cyclase-C Agonist
  • Somatostatin Analogue
  • Others
  • Global Oral Biologics Market, By Disease Indication:
  • Diabetes
  • Hyperoxaluria
  • Acromegaly
  • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
  • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
  • Global Oral Biologics Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Oral Biologics Market, By Region:
  • North America

? By Drug Class

? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist

? Hormone

? Recombinant Enzyme

? Guanylate Cyclase-C Agonist

? Somatostatin Analogue

? Others

? By Disease Indication

? Diabetes

? Hyperoxaluria

? Acromegaly

? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)

? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)

? By Distribution Channel

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country

? U.S.

? Canada

  • Latin America

? By Drug Class

? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist

? Hormone

? Recombinant Enzyme

? Guanylate Cyclase-C Agonist

? Somatostatin Analogue

? Others

? By Disease Indication

? Diabetes

? Hyperoxaluria

? Acromegaly

? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)

? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)

? By Distribution Channel

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country

? Brazil

? Mexico

? Argentina

? Rest of Latin America

  • Europe

? By Drug Class

? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist

? Hormone

? Recombinant Enzyme

? Guanylate Cyclase-C Agonist

? Somatostatin Analogue

? Others

? By Disease Indication

? Diabetes

? Hyperoxaluria

? Acromegaly

? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)

? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)

? By Distribution Channel

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country

? Germany

? U.K.

? France

? Italy

? Spain

? Russia

? Rest of Europe

  • Asia Pacific

? By Drug Class

? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist

? Hormone

? Recombinant Enzyme

? Guanylate Cyclase-C Agonist

? Somatostatin Analogue

? Others

? By Disease Indication

? Diabetes

? Hyperoxaluria

? Acromegaly

? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)

? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)

? By Distribution Channel

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country

? China

? India

? Japan

? Australia

? South Korea

? ASEAN

? Rest of Asia Pacific

  • Middle East

? By Drug Class

? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist

? Hormone

? Recombinant Enzyme

? Guanylate Cyclase-C Agonist

? Somatostatin Analogue

? Others

? By Disease Indication

? Diabetes

? Hyperoxaluria

? Acromegaly

? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)

? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)

? By Distribution Channel

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country

? GCC

? Israel

? Rest of Middle East

  • Africa

? By Drug Class

? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist

? Hormone

? Recombinant Enzyme

? Guanylate Cyclase-C Agonist

? Somatostatin Analogue

? Others

? By Disease Indication

? Diabetes

? Hyperoxaluria

? Acromegaly

? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)

? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)

? By Distribution Channel

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country

? South Africa

? Central Africa

? North Africa

  • Company Profiles
  • Novo Nordisk A/S *

? Company Overview

? Product Portfolio

? Financial Overview

? Key Highlights

? Market Strategies

  • Biocon Limited
  • Oramed Pharmaceuticals, Inc.
  • Rani Therapeutics
  • Entera Bio Ltd.
  • AbbVie Inc.
  • Enteris BioPharma, Inc.
  • Chiasma, Inc.
  • Allena Pharmaceuticals, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI989

Table of Contents

1. Research Objective and Assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
    • Market Definition and Scope
    • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Disease Indication
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • PEST Analysis
    • Adherence of Patients- Injectable Biologics
    • Regulatory Scenario
    • Limitations of Injectable Biologics
    • Epidemiology
    • Mechanism of Action- Pill Technology
    • Partnership/Collaboration/Acquisition/Agreement

4. Global Oral Biologics Market, By Drug Class, 2017 - 2028 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
    • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Hormone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Recombinant Enzyme
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Guanylate Cyclase-C Agonist
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Somatostatin Analogue
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

5. Global Oral Biologics Market, By Disease Indication, 2017 - 2028 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
    • Diabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Hyperoxaluria
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Acromegaly
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global Oral Biologics Market, By Distribution Channel, 2017 - 2028 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
    • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global Oral Biologics Market, By Region, 2017 - 2028 (US$ Mn)

    • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
    • North America
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • U.S.
    • Canada
    • Europe
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
    • Latin America
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Africa
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
    • Middle East
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

    • Heat Map Analysis
    • Company Profiles
    • Novo Nordisk A/S
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Biocon Limited
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Oramed Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Rani Therapeutics
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Entera Bio Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Allergan plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Emisphere Technologies, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Enteris BioPharma, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Chiasma, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Allena Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

    • References
    • Research Methodology
    • About us and Sales Contact